 SAN DIEGO, April 28, 2022 GLOBE NEWSWIRE -- Histogen Inc. NASDAQ: HSTO, a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogens financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022. 